2021, Number 1
<< Back Next >>
Rev cubana med 2021; 60 (1)
New molecular and pathophysiological aspects of sickle cell anemia
Soler NG, Escalona MLZ, Peña LK
Language: Spanish
References: 29
Page: 1-10
PDF size: 434.23 Kb.
ABSTRACT
Introduction: Hemoglobin S disease is a hereditary chronic hemolytic anemia whose clinical
manifestations come from the tendency of this hemoglobin to polymerize and deform
erythrocytes, giving the typical crescent, banana, sickle cell or "sickle cell" shape; hence the name
sickle cell anemia or sicklemia.
Objective:v To describe the new molecular and pathophysiological aspects and the diagnosis of
sickle cell anemia.
Methods: A literature review was carried out, in English and Spanish, through PubMed website and Google academic search engine for articles published in the last 10 years. An analysis and summary
of the revised bibliography was made.
Conclusions: Understanding the complexity and multiplicity of events that lead to serious
complications in sickle cell anemia and our inability to predict the clinical course in each
particular case would help preventing these events.
REFERENCES
Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle celldisease. Nature Reviews Disease Primers. 2018;4:18010.
Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing globalhealth importance. Arch Dis Child. 2015;100:48-53. http://doi.org/10.1136/archdischild-2013-303773
Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN. et al. Global distribution ofthe sickle cell gene and geographical confirmation of the malaria hypothesis. Naturecommunications. 2010;1:104. http://doi.org/:10.1038/ncomms1104
Kato GJ. New Insights into Sickle Cell Disease: Mechanisms and Investigational Therapies.Current opinion in hematology. 2016;23(3):224-32.http://doi.org/10.1097/MOH.0000000000000241
Das R, Mitra A, Mitra G, Maity D, Bhat V, Pal D, et al. Molecular insights of inhibition in sicklehemoglobin polymerization upon glutathionylation: hydrogen/deuterium exchange massspectrometry and molecular dynamics simulation based approach. Biochemical Journal. 2018;BCJ20180306. http://doi.org/10.1042/BCJ20180306
Eaton WA, Bunn HF. Treating sickle cell disease by targeting HbS polymerization. Blood. 2017;blood-2017-02-765891. http://doi.org/10.1182/blood-2017-02-765891
Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376:1561-73.http://doi.org/10.1056/NEJMra1510865
Esin Al, Bergendah lLT, Savolainen V, Marsh J, Warnecke T. The genetic basis and evolution ofred blood cell sickling in deer. Nature Ecology & Evolution. 2018;2:367-76.http://doi.org/10.1038/s41559-017-0420-3
Garneau AP, Marcoux AA, Frenette-Cotton R, Mac-Way F, Lavoie JL, Isenring P. Molecularinsights into the normal operation, regulation, and multisystemic roles of K+-Cl−cotransporter 3 (KCC3). American Journal of Physiology. 2017;3131(5):516-32.http://doi.org/10.1152/ajpcell.00106.2017
Postgraduate Haematology, FifthEdition. Edited by A. Victor Hoffbrand, Daniel Catovsky,Edward G.D. Tuddenham. Copyright © 2005 Blackwell Publishing Ltd, 9600 Garsington Road,Oxford OX4 2DQ, UK.
Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, et al. A Multinational Trial ofPrasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine. 2016[acceso:15/05/2020];374(7):625-35. Disponible en:https://www.nejm.org/doi/full/10.1056/NEJMoa1512021
Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sicklecell disease. J Clin Invest. 2017;127(3):750-60. http://doi.org/10.1172/JCI89741
Nayar S, Acharya S, Acharya R, Kishore S, Thakur B. Spectrum of Haemoglobinopathies: AHospital Based Study in Uttarakhand. Journal Of Clinical & Diagnostic Research. 2017;11(12):18-21. http://doi.org/10.7860/JCDR/2017/31731.10947
Garnier Y, Ferdinand S, Etienne-Julan M, Elana G, Petras M, Doumdo L, et al. Differences ofmicroparticle patterns between sickle cell anemia and hemoglobin SC patients. PLoS ONE.2017;12(5):0177397. http://doi.org/10.1371/journal.pone.0177397
Lin MI, Paik E, Mishra B, Burkhardt D, Kernytsky A, Pettiglio M, et al. CRISPR/Cas9 GenomeEditing to Treat Sickle Cell Disease and B-Thalassemia: Re-Creating Genetic Variants to UpregulateFetal Hemoglobin Appear Well-Tolerated, Effective and Durable. Blood. 2017[acceso:15/05/2020];130(S1):284. Disponible en: http://www.bloodjournal.org/content/130/Suppl_1/284
Opi DH, Ochola LB, Tendwa M, Siddondo BR, Ocholla H, Fanjo H, et al. Mechanistic studies ofthe negative epistatic malaria-protective interation between sickle cell trait and α+thalasaemia.EBio Medicine. 2014;1(1):29-36. http://doi.org/10.1016/j.ebiom.2014.10.006
Rivera-Paz EE, Espinal-Palacios AG, Palencia EP, Hernández AP. Anemia de células falciformescon persistencia de hemoglobina fetal como factor protector: reporte de caso. Rev Mex Pediatr.2016;82(2):55-9.
Lin MI, Paik EJ, Mishra BP, Chou S, Zhang Y, Tomkinson K, et al. Re-Creating HereditaryPersistence of Fetal Hemoglobin (HPFH) to Treat Sickle Cell Disease (SCD) and β-Thalassemia.Blood. 2016[acceso: 15/05/2020];128(22):4708. Disponible en:http://www.bloodjournal.org/content/128/22/4708
Paglietti ME, Satta S, Sollaino MC, Barella S, Ventrella A, Desogus MF, et al. The Problem ofBorderline Hemoglobin A2 Levels in the Screening for β-Thalassemia Carriers in Sardinia. ActaHaematol. 2016;135:193-9.
Italia K, Upadhye D, Dabke P, Kangane H, Colaco S, Sawant P, et al. Clinical and hematologicalpresentation among indian patients with common hemoglobin variants. Clinica Quimica Acta.2014;431:46-51. http://doi.org/10.1016/j.cca.2014.01.028
Bezirgiannidou Z, Christoforidou A, Kontekaki E, Anastasiadis AG, Papamichos SI, Menexidou H,et al. Hyperhemolytic Syndrome Complicating a Delayed Hemolytic Transfusion Reaction due toanti-P1 Alloimmunization, in a Pregnant Woman with HbO-Arab/β-Thalassemia. MediterraneanJournal of Hematology and Infectious Diseases. 2016;8(1):e2016053.http://doi.org/10.4084/MJHID.2016.053
Chotivanich K, Udomsangpetch R, Pattanapanyasat K, Chierakul W, Simpson J, LooareesuwanS, et al. Hemoglobin E: a balanced polymorphism protective against high parasitemias and thussevere P. falciparum malaria. Blood. 2002[acceso: 15/05/2020];100(4):1172-6. Disponible en:http://www.bloodjournal.org/content/100/4/1172
Erramouspe B, Eandi Eberle SJ. Conventional techniques applied to the diagnosis ofhemoglobinopathies. Acta bioquím clín latinoam. 2017[acceso: 15/05/2020];51(3):325-32.Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-29572017000300007&lng=es
Noubouossie D, NS Key, Ataga KI. Coagulation abnormalities of sickle cell disease: Relationshipwith clinical outcomes and the effect of disease modifying therapies. Blood Review.2016;30(4):245-56. http://doi.org/10.1016/j.blre.2015.12.003
Yoon CS, Tan YM, Law HY. AB091. Comparison of two haemoglobin electrophoresis platformsfor the detection of haemoglobinopathies. Annals of Translational Medicine. 2017;5(S2):AB091.http://doi.org/10.21037/atm.2017.s091
Begum K, Mannan MA, Sanyal M, Hosen I, Chakraborty S, Shekhar H. Molecular DiagnosticApproach Prevails Superior Over Conventional Gel-Electrophoresis Method in Detecting Sickle CellAnemia. J Mol Biomark Diagn. 2018;9:382. http://doi.org/10.4172/2155-9929.1000382
McGann PT, Hoppe C. The pressing need for point-of-care diagnostic for sickle cell disease: Areview of current and future technologies. Blood Cells Molecules and Diseases. 2017;67:104-13.http://doi.org/10.1016/j.bcmd.2017.08.010
Traeger-Synodinos J, Harteveld CL, Old JM, Petrou M, Galanello R, Giordano P, et al. EMQNBest Practice Guidelines for molecular and haematology methods for carrier identification andprenatal diagnosis of the haemoglobinopathies. European Journal of Human Genetics.2015;23:426-37. http://doi.org/10.1038/ejhg.2014.131
Camilo-Araújo RF, Silverio Amancio OM, Figueiredo MS, Cabanãs-Pedro AC, Pellegrini Braga JA.Molecular analysis and association with clinical and laboratory manifestations in children withsickle cell anemia. Rev Bras Hematol Hemoter. 2014;36(5): 334-9.http://doi.org/10.1016/j.bjhh.2014.06.002